Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2026 event, please get in touch at info@hansonwade.com.
The Leading Industry Event Driving Next-Generation Psychosis R&D
Uniting Biotech & Pharma Leaders Transforming Psychosis Drug Development
2025 has been a pivotal year for psychosis drug development, with a surge in clinical advancements and growing momentum from key collaborations since 2024. There has never been a better time for a dedicated forum for the R&D scientists paving the way in novel psychosis drug discovery and development.
Uniquely positioned to address the hurdles in translational validity, patient heterogeneity, placebo effect and scaling trials, the Innovation in Psychosis Therapeutics Summit 2025 was a brand new opportunity to collaborate with 60+ leading experts across discovery, preclinical, translational and clinical development.
With the rising unmet need to address the burden of psychosis and the significant side effects associated with atypical antipsychotics, this summit was a key moment to build on Cobenfy’s breakthrough success and collaboratively drive the development of next generation approaches for targeting psychosis across the disease spectrum.
2025 World-Class Speaker Faculty:
Past Speaker
“I am looking forward to attending the conference, as it is poised to capture the excitement as well as challenges and complexities associated with the arrival of muscarinic compounds for the treatment of psychosis.”
Mikhail Kalinichev, Head of Translational Science,
Neurosterix
Proud to Partner With in 2025:
Other Events in the Series
